Triple negative breast cancer (TNBC) represents the 15–20% of all breast cancers (BC) and
is characterized by a very aggressive behavior. Recent data suggest that TNBC is not a …

Gene silencing via RNA interference (RNAi) is rapidly evolving as a personalized approach
to cancer treatment. The effector molecules—small interfering RNAs (siRNAs) and …

Among different types of breast cancers (BC), triple-negative BC (TNBC) amounts to 15% to
20% of breast malignancies. Three principal characteristics of TNBC cells are (i) extreme …

Objective To investigate whether radiomics features extracted from multi-parametric MRI
combining machine learning approach can predict molecular subtype and androgen …

Abstract Lessons Learned The combination of enobosarm and pembrolizumab was well
tolerated and showed a modest clinical benefit rate of 25% at 16 weeks. Future trials …

Breast cancer (BC) is still characterized by high morbidity and mortality. A specific BC
subtype named triple negative BC (TNBC) lacks estrogen and progesterone receptors (ER …

The androgen receptor (AR) has been found to be expressed in the majority of human
breast cancer and AR antagonists, such as enzalutamide, have shown promising clinical …

The principle steroidal androgens are testosterone and its metabolite 5α-
dihydrotestosterone (DHT), which is converted from testosterone by the enzyme 5α …

Purpose: Androgen receptor (AR) expression has been observed in about 70% of patients
with breast cancer, but its prognostic role remains uncertain. Experimental Design: To …

Breast cancer is the most common malignancy in women all over the world. Genetic
background of women contributes to her risk of having breast cancer. Certain inherited DNA …